1. Field of the Invention
The present invention relates generally to tissue treatment systems and in particular to distribution manifolds for wound treatment.
2. Description of Related Art
Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifolding device. The porous pad contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad often is incorporated into a dressing having other components that facilitate treatment.
Distribution manifolds for delivering reduced pressure treatment are also commonly referred to as reduced pressure dressings, or in the case of treatment of a wound, wound dressings. Such dressings are characterized by structural features that allow fluid flow through the material. For example, one material that is often used as a wound dressing is reticulated, open-cell polyurethane foam. The foam includes a plurality of interconnected pores that allow fluid flow throughout the foam. When a reduced pressure is applied to one area of the foam, this reduced pressure is quickly distributed to other areas of the foam and is easily transmitted to tissues adjacent the foam. One problem with open-cell foams and similar materials is tissue in-growth, which prevents easy removal of the foam following treatment. For open cells foams with pore sizes on the order of 100-1000 microns, in-growth of tissue may occur relatively quickly. As the new tissue enters the pores or cells of the foam, the foam acts as a lattice, and tissue grows within the pores and around the walls and/or starts that form the perimeter of the pores. This effectively attaches the foam to the tissue site, and the foam must be forcibly removed by tearing the new tissue and breaking any bonds that have formed between the tissue and the foam. Not only is this detrimental to the healing process, but the tearing of this tissue may cause discomfort to the patient.
One way to circumvent the problem of tissue in-growth is to increase the frequency of dressing changes. If new dressings are applied with increased frequency, there is less tissue in-growth, and thus less disruption of new tissue upon removing the old dressing. One downside to increased dressing changes is the increased costs associated with materials (i.e. new dressings) and labor. Changing a dressing is labor intensive and diverts the attention of medical personnel from other important tasks. Increased dressing changes also result in more aggravation to patients and their wounds.
The problems presented by existing reduced pressure treatment systems are solved by the systems and methods of the illustrative embodiments described herein. In one embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of protrusions positioned on a first side of the backing substrate with each of the protrusions having substantially circular cross-sectional shape and having a diameter of between about 0.1 and 2.0 millimeters. The backing substrate has a plurality of apertures formed therein to allow fluid communication between the first side and a second side opposite the first side. A reduced pressure source fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to the tissue.
In another embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of protrusions positioned on a first side of the backing substrate, each of the protrusions having substantially polygonal cross-sectional shape and having a width of between about 0.1 and 2.0 millimeters. The backing substrate has a plurality of apertures formed therein to allow fluid communication between the first side and a second side opposite the first side. A reduced pressure source fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to the tissue.
In another embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of columnar voids positioned on a first side of the backing substrate, each of the columnar voids having substantially polygonal cross-sectional shape and having a width of between about 0.1 and 2.0 millimeters.
In another embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of protrusions positioned on a first side of the backing substrate, each of the protrusions having substantially circular cross-sectional shape and tapering inward from the base at which the protrusions meet the backing substrate. The backing substrate has a plurality of apertures formed therein to allow fluid communication between the first side and a second side opposite the first side. A reduced pressure source fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to the tissue.
Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of the illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.
The several embodiments of the present invention described herein are provided to assist in the healing of wounds and generation of new tissue. Reduced pressure therapy is administered to patients with a reduced pressure delivery system. This form of advanced wound healing therapy can be readily integrated into a clinician's wound healing procedures. The therapy optimizes patient care and decreases costs associated with treatment of patients having traumatic and chronic wounds. With the innovative embodiments of the reduced pressure delivery system described herein, reduced pressure therapy can be administered either in the hospital, in community settings such as assisted living complexes and convalescence homes, or in the home.
Reduced pressure delivery to a wound or tissue site promotes wound healing and/or tissue growth by removing infectious materials and other fluids from the wound or tissue site. Reduced pressure treatment further promotes tissue growth by imposing forces on the tissue, thereby causing micro-deformation of the tissue, which is believed to contribute to the development of granulation tissue at the tissue site. The forces imposed on the tissue site by the delivery of reduced pressure further encourage improved blood flow to the tissue site, which further assists in the growth of new tissue.
Referring to
Referring to
Referring more specifically to
The shape, sizing, and spacing of the protrusions 51 may vary depending upon the particular tissue site 31 being treated, the type of material from which the protrusions 51 and backing substrate 41 are made, and the amount of reduced pressure being applied to the tissue site 15. For example, for tissue sites that are highly exudating, it may be advantageous to position the protrusions farther apart to maintain adequate distribution channels 61 between the protrusions 51. In one embodiment of the present invention, the shape, sizing and spacing of the protrusions 51 is uniform for a particular distribution manifold 15. In other embodiments, the shape, sizing, and spacing of the protrusions 51 may var. For example, protrusions 51 having different cross-sectional shapes may be disposed on the backing substrate 41. Similarly, the sizing and spacing of the protrusions 51 may vary to supply selected portions of the tissue site 31 with more or less reduced pressure.
The presence and sizing of the protrusions 51 allow the protrusions 51 to distribute reduced pressure to the tissue site 31, but prevent new tissue that grows at the tissue site 31 from attaching to the protrusions 51 of the distribution manifold 15. By eliminating the pores that are typically used to deliver reduced pressure to a tissue site, new tissue is not able to wrap around the walls that form the pores. While new tissue growth will grow into the field of protrusions 51 and may even wrap around some of the protrusions 51, the new tissue is not capable of securing itself to the protrusions 51 since the base of each protrusion is anchored to the backing substrate 41.
In addition to distributing reduced pressure to the tissue site 31, the distribution manifold 15 also serves to impart stresses and strains to the tissue site 31 similar to those seen with cellular foam that traditionally has been used in reduced pressure systems. Other materials sometimes used in reduced pressure systems as distribution manifolds, such as gauze, do not have this effect on tissue. The stresses and strains created by the distribution manifold 15 are believed to cause micro-deformation of existing tissue and play a significant role in the generation of new tissue at the tissue site. The amount of stress and strain imparted to a tissue site is determined by the amount of reduced pressure supplied to the tissue site and the surface morphology of the manifold that contacts the tissue site. As reduced pressure is applied, portions of the tissue site are pulled against the distribution manifold 15, and more particularly against the protrusions 51, which results in the development of stresses and strains within the tissue. The sizing of the protrusions 51 on a scale similar to that of the pores of the cellular foam is believed to be one reason for the development of stresses and strains that are similar to those seen with use of the foam.
In one embodiment, the backing substrate 41 is formed from the same material as the protrusions 51. Preferably, that material is silicone or another medical grade material that is relatively impermeable to fluid flow. Alternatively, the material may be a semi-permeable material that allows select fluids or amounts of fluids to pass. The backing substrate 41 preferably includes a plurality of apertures 71 that allow distribution from a surface of backing substrate 41 opposite the protrusions 51 to the tissue contact surface 43 from which the protrusions 51 extend. Since the presence of the apertures 71 could have the same effect on tissue in-growth as that of pores, it is important that the backing substrate 41 and protrusions 51 be removed from the tissue site 31 prior to any new tissue advancing into the apertures 71. In practice, this may be accomplished by knowing the approximate rate of tissue growth, the height of the protrusions 51, and determining the amount of time likely required for new tissue growth to reach the apertures 71.
While the distribution manifold 15 has primarily been described as including backing substrate 41 and plurality of protrusions 51, the distribution manifold 15 may further include cellular foam or other material that is positioned adjacent to or attached to the surface of the backing substrate 41 opposite the protrusions 51. The use of a cellular foam or other material increases the ability of the reduced pressure conduit 19 or the distribution adapter 35 to deliver and distribute reduced pressure to the backing substrate 41. The protrusions 51 and backing substrate 41 serve as a barrier to new tissue growth entering pores of the cellular foam or other material.
Referring to
The shape and size of the voids 151 may be similar to that of the protrusions 51 of manifold 15. As previously described, a cellular foam, distribution adapter, or other manifolding device may be placed in fluid communication with the distribution channels 161 to deliver reduced pressure to the tissue site.
Exemplary Distribution Manifold having Protrusions
Referring to
The sizing of the protrusions 215 is such that on the two inch diameter backing substrate 241, approximately 7500 protrusions are present. The width of each protrusion at the base is about 0.5 mm, the height of each protrusion is about 1.5 mm, and the lateral center-to center spacing between the protrusions is about 0.75 mm. The ratio of height to width of the protrusions is about 3:1, and the ratio of the spacing to width is about 1.5:1. The tapering of each protrusion 51 is about a five degree draft angle from the longitudinal axis of the protrusions 51 to aid in molding the distribution manifold 215.
Distribution manifold 215 was sized based on an expected rate of tissue growth and the desired period of use between changes of the distribution manifold 215. For reduced pressures of about 125 mm Hg, one to two millimeters of tissue growth may be expected over a 48 hour period. Since it is desired to change the distribution manifold 215 every 48 hours, a protrusion height of about 1.5 mm allows the majority of the spacing between the protrusions 251 to fill with new tissue growth between dressing changes, but prevents the tissue from attaching to the distribution manifold 251.
Referring more specifically to
Exemplary Distribution Manifold having Voids
Referring to
It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
This application claims the benefit of U.S. Provisional Application No. 60/928,644, filed May 10, 2007, which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2305289 | Coburg | Dec 1942 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3026874 | Stevens | Mar 1962 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3089492 | Owens | May 1963 | A |
3142298 | Koski et al. | Jul 1964 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4250882 | Adair | Feb 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261360 | Perez | Apr 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4342745 | Mirkovitch | Aug 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4444545 | Sanders et al. | Apr 1984 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4468219 | George et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4533352 | Van Beek et al. | Aug 1985 | A |
4534356 | Papadakis | Aug 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4614183 | McCracken et al. | Sep 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4795435 | Steer | Jan 1989 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt et al. | Apr 1990 | A |
4930997 | Bennett | Jun 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4979944 | Luzsicza | Dec 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5013300 | Williams | May 1991 | A |
5034006 | Hosoda et al. | Jul 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5195977 | Pollitt | Mar 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5260066 | Wood et al. | Nov 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5449347 | Preen et al. | Sep 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5678564 | Lawrence et al. | Oct 1997 | A |
5735833 | Olson | Apr 1998 | A |
5762640 | Kajiwara et al. | Jun 1998 | A |
5776119 | Bilbo et al. | Jul 1998 | A |
5827246 | Bowen | Oct 1998 | A |
5902260 | Gilman et al. | May 1999 | A |
5941859 | Lerman | Aug 1999 | A |
6051747 | Lindqvist et al. | Apr 2000 | A |
6071267 | Zamierowski | Jun 2000 | A |
6080243 | Insley et al. | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6471982 | Lydon et al. | Oct 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6566575 | Stickels et al. | May 2003 | B1 |
6572594 | Satterfield et al. | Jun 2003 | B2 |
6660484 | Charych et al. | Dec 2003 | B2 |
6682506 | Navarro | Jan 2004 | B1 |
6695823 | Lina et al. | Feb 2004 | B1 |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7117869 | Heaton et al. | Oct 2006 | B2 |
7195624 | Lockwood et al. | Mar 2007 | B2 |
7273054 | Heaton et al. | Sep 2007 | B2 |
7276051 | Henley et al. | Oct 2007 | B1 |
7344512 | Yamazaki et al. | Mar 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7396339 | Britto et al. | Jul 2008 | B2 |
7651484 | Heaton et al. | Jan 2010 | B2 |
7670323 | Hunt et al. | Mar 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7867206 | Lockwood et al. | Jan 2011 | B2 |
7886746 | Heaton et al. | Feb 2011 | B2 |
20020065494 | Lockwood et al. | May 2002 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020161346 | Lockwood et al. | Oct 2002 | A1 |
20030108587 | Orgill et al. | Jun 2003 | A1 |
20040073151 | Weston | Apr 2004 | A1 |
20040127836 | Sigurjonsson et al. | Jul 2004 | A1 |
20050004534 | Lockwood et al. | Jan 2005 | A1 |
20050261642 | Weston | Nov 2005 | A1 |
20050283105 | Heaton et al. | Dec 2005 | A1 |
20070118096 | Smith et al. | May 2007 | A1 |
20080275409 | Kane et al. | Nov 2008 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Apr 1999 | AU |
755496 | Feb 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
39 07 007 | Sep 1990 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Oct 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0300621 | Jan 1989 | EP |
0358302 | Mar 1990 | EP |
1018967 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 333 965 | Aug 1999 | GB |
2 329 127 | Aug 2000 | GB |
A-59-141943 | May 1984 | JP |
4129536 | Apr 1992 | JP |
2242956 | Dec 2004 | RU |
71559 | Apr 2002 | SG |
WO 8002182 | Oct 1980 | WO |
WO 8704626 | Aug 1987 | WO |
WO 90-10424 | Sep 1990 | WO |
WO 9309727 | May 1993 | WO |
WO 9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9718007 | May 1997 | WO |
WO 9913793 | Mar 1999 | WO |
WO 0134223 | May 2001 | WO |
WO 0137922 | May 2001 | WO |
WO 0185248 | Nov 2001 | WO |
WO 0189431 | Nov 2001 | WO |
WO 03045492 | Jun 2003 | WO |
WO 03057070 | Jul 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20080300555 A1 | Dec 2008 | US |
Number | Date | Country | |
---|---|---|---|
60928644 | May 2007 | US |